Q: How common is 5-FU toxicity?
A: As many as 1 in 3 patients receiving 5-FU–related therapy experience dose-limiting toxicity that is largely avoidable.
Q: What is the prevalence of clinically important DPYD and TYMS variants?
A: Up to 25% (1/4) of individuals have variations in the DPYD and/or TYMS genes that are associated with an increased risk of toxicity to 5-FU.
Q: What is the risk of toxicity due to DPYD and TYMS?
A: Variations in the DPYD and TYMS genes are associated with up to a 60% risk of dose-limiting toxicity to 5-FU or capecitabine therapy.
Q: Am I a candidate for TheraGuide 5-FU™ testing?
A: Any patient being considered for 5-FU/capecitabine therapy is a candidate for TheraGuide 5-FU™. There is a tremendous benefit to determining toxicity risk prior to starting 5-FU chemotherapy, or at the beginning of your regimen. By assessing the risk of 5-FU toxicity, your doctor can identify patients who may not effectively metabolize 5-FU/capecitabine and thereby provide an individualized treatment plan for you.
Q: How is the TheraGuide 5-FU™ test performed?
A: TheraGuide 5-FU™ is a simple blood test that detects variations in the DPYD and TYMS genes in order to predict the patient's risk for 5-FU toxicity.
Q: Why is TheraGuide 5-FU™ different?
A: TheraGuide™ 5-FU is the most comprehensive test for assessing the risk of 5-FU toxicity caused by these genes and is the only diagnostic test that includes full sequencing of DPYD, as well as analysis of the TYMS gene.
Q: Is TheraGuide 5-FU™ clinically validated?
A: Yes, the results are clinically validated and performed in our CLIA-certified laboratory.
